262 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
VRTX Vertex Pharmaceuticals Incorporated $165.9 $42.12B Downtrend
Article Searches
Your Daily Pharma Scoop: Dynavax Achieves Major Milestone, GW Pharmaceuticals GWP42006 Fails, Sangamo Signs Deal With Gilead's Kite Unit https://seekingalpha.com/article/4149469-daily-pharma-scoop-dynavax-achieves-major-milestone-gw-pharmaceuticals-gwp42006-fails-sangamo?source=feed_sector_healthcare Feb 23, 2018 - Dynavax’s commercialization efforts with HEPLISAV-B get a boost.GW Pharmaceuticals’ GWP42006 fails in proof-of-concept study.Sangamo inks a deal with Gilead’s Kite Pharma unit.
The Zacks Analyst Blog Highlights: Amgen, TOTAL, Marriott, PG&E and Vertex http://www.zacks.com/stock/news/293070/the-zacks-analyst-blog-highlights-amgen-total-marriott-pge-and-vertex?cid=CS-ZC-FT-293070 Feb 21, 2018 - The Zacks Analyst Blog Highlights: Amgen, TOTAL, Marriott, PG&E and Vertex
Bulletproof Investing Performance: Week 12 https://seekingalpha.com/article/4148699-bulletproof-investing-performance-week-12?source=feed_all_articles Feb 21, 2018 - Portfolio Armor's top 10 names from week 12 (August 17th) underperformed SPY over the next 6 months, breaking a streak of outperforming SPY over the last 9 weekly cohorts. All three hedged portfolios
Top Analyst Report for Amgen, TOTAL S.A. & Marriott http://www.zacks.com/research-daily/149986/top-analyst-report-for-amgen-total-sa-marriott?cid=CS-ZC-FT-149986 Feb 20, 2018 - Top Analyst Report for Amgen, TOTAL S.A. & Marriott
Biotechs: Still Well Placed For More Gains https://seekingalpha.com/article/4148492-biotechs-still-well-placed-gains?source=feed_all_articles Feb 20, 2018 - Sharp market correction triggered by interest rate concerns creates opportunities.Market transitions into a more typical rally and pullback mode, with a continued firm uptrend.Biotech stocks are exper
Celgene's Otezla-Colitis Story; Implications For Other Biotechs https://seekingalpha.com/article/4147853-celgenes-otezla-colitis-story-implications-biotechs?source=feed_tag_editors_picks Feb 16, 2018 - CELG put out an optimistically-titled press release regarding a mid-stage clinical trial for its newest blockbuster, Otezla.My interpretation of the data is at variance with that of CELG.I see CELG do
Sphera Funds Management Ltd. Buys Mylan NV, Alexion Pharmaceuticals Inc, Amicus Therapeutics ... http://www.gurufocus.com/news/640021/sphera-funds-management-ltd-buys-mylan-nv-alexion-pharmaceuticals-inc-amicus-therapeutics-inc-sells-gilead-sciences-inc-biogen-inc-ituran-location-and-control Feb 12, 2018 - Sphera Funds Management Ltd. Buys Mylan NV, Alexion Pharmaceuticals Inc, Amicus Therapeutics Inc, Sells Gilead Sciences Inc, Biogen Inc, Ituran Location and Control, Stocks: FOLD,VRTX,VKTX,PRTA,SAGE,DCPH,MYL,ALXN,GLYC,ACAD,O, release date:Feb 12, 2018
Corbus Buying Opportunity As Shares Fall With Biotech Sector On $25M Cystic Fibrosis Grant https://seekingalpha.com/article/4145797-corbus-buying-opportunity-shares-fall-biotech-sector-25m-cystic-fibrosis-grant?source=feed_sector_healthcare Feb 12, 2018 - Corbus Pharmaceuticals recently announced a $25M grant from the Cystic Fibrosis Foundation to fund a large Phase II clinical trial with pulmonary exacerbations as the primary endpoint.The announcement
Crispr Therapeutics: Is There Something Else Behind The Potential Gilead Acquisition? https://seekingalpha.com/article/4145716-crispr-therapeutics-something-else-behind-potential-gilead-acquisition?source=feed_sector_healthcare Feb 12, 2018 - Gilead Sciences recently disclosed that the company is in discussion to potentially acquire a gene-editing company.Bill Lundberg, M.D., recently stepped down as chief scientific officer to serve as se
Mergers And Acquisitions: Is There A Pending Catalyst For Crispr Therapeutics? https://seekingalpha.com/article/4145046-mergers-acquisitions-pending-catalyst-crispr-therapeutics?source=feed_sector_healthcare Feb 09, 2018 - Gilead is poised for the upcoming growth with various key catalysts such as NASH, HCV's expansion into China, and CAR-T.A notable growth catalyst was the Kite Pharma acquisition in 2017. The company i

Pages: 123456...27

Page 1>

Related Companies

Name Exchange Price Mkt Cap
ZTS Zoetis Inc. NYSE $82.79 $40.17B
SHPG Shire plc NASDAQ $127.08 $38.55B
REGN Regeneron Pharmaceuticals, Inc. NASDAQ $323.86 $34.88B
AGN Allergan plc. NYSE $162.09 $53.54B
ALXN Alexion Pharmaceuticals, Inc. NASDAQ $118.93 $26.36B
Sector: Health Care > Industry: Major Pharmaceuticals
DeepLinks for Vertex Pharmaceuticals Incorporated
VRTX - Google Finance https://www.google.com/finance?q=VRTX Industry related info and international coverage Summary News
VRTX - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=VRTX Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options